Table 4.
In Vivo Efficacy of WCK 771 in a Mouse Systemic Infection Model
| Infecting Strain | SC Route | Oral Route | ||
|---|---|---|---|---|
| ED50 (mg/kg) | ED90 (mg/kg) | ED50 (mg/kg) | ED90 (mg/kg) | |
| S. aureus ATCC 25923 | 0.59 | 1.08 | 2.8 | 4.37 |
| S. aureus Smith (ATCC 13709) | 0.86 | 2.4 | 1.7 | 5.0 |
| S. aureus 1199 NorA− | 2.2 | 3.1 | 2.2 | 3.1 |
| S. aureus 1199B NorA+ | 3.04 | 6.6 | 3.04 | 6.6 |
| S. aureus 5023 (MRSA) | 33.9 | 48.6 | Not Studied | |
| S. aureus 33 (MRSA) | 38.3 | 70.4 | ||
| S. aureus 34 (MRSA) | 44.6 | 62.3 | ||
| S. aureus 5002 (MRSA) | 46.8 | 56.8 | ||
| S. aureus 32 (MRSA) | 27.8 | 62.1 | ||
| S. aureus 97 (MRSA) | 46.8 | 56.8 | ||
Note: Data From: Patel MV, De Souza NJ, Gupte SV, et al.Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother. 2004;48(12):4754–4761.39